Exclusive Summary

• - EU-27 registration enables immediate distribution deals and fast access to multi-country hospital tenders.
• - First-line therapy for invasive aspergillosis and listed on the WHO Essential Medicines List, with IV preferred for initial treatment in severe cases.
• - Global severe fungal disease demand is in the hundreds of thousands annually, covering transplant, hematology, and ICU populations with high per-patient IV consumption.
• - 200mg/20mL IV presentation fits loading/maintenance dosing and streamlines pharmacy preparation, supporting IV-to-oral step-down.
• - With originator patents long expired and broad generic competition, EU-grade quality, reliable supply, and pricing advantage position the product well for tenders and distributors.